This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's How J&J (JNJ) Will Roll Out Drug Sector Q3 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while the Medical Devices segment might have been hurt by the COVID-19 impact in the third quarter.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $87.07, marking a +1.37% move from the previous day.
ImmunoGen's Rare Blood Cancer Candidate Gets Breakthrough Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on ImmunoGen's (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise.
Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - October 05, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Simple Secrets Anyone Can Use to Reach Early Retirement - October 05, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs
by Kinjel Shah
New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.
J&J Simponi Aria Gets FDA Nod for Pediatric Use in Arthritis
by Zacks Equity Research
FDA approves J&J's (JNJ) Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) in patients two years of age and older.
Ironwood to End IW-3718 Development After Study Failure
by Zacks Equity Research
Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.
The Extreme Risks of Trading Your Own Retirement Assets - September 30, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Aerie to Initiate Phase IIb Study for Dry Eye Treatment
by Zacks Equity Research
The FDA accepts Aerie's (AERI) investigational new drug application for AR-15512 eye drop for dry eye disease.
AbbVie Elezanumab Gets FDA's Fast Track and Orphan Drug Tags
by Zacks Equity Research
AbbVie's (ABBV) elezanumab is presently being evaluated in a phase II study for spinal cord injury.
Pfizer's (PFE) Xeljanz Gets FDA Approval for 4th Indication
by Zacks Equity Research
Pfizer's (PFE) Xeljanz gets approval for children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $87.28, moving +1.22% from the previous trading session.
Gilead & Galapagos' RA Drug Receives Approval in Europe
by Zacks Equity Research
Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.
Galapagos Gets First Commercial Drug With Jyseleca Approval
by Zacks Equity Research
Galapagos (GLPG) and Gilead announce approval of Jyseleca in Europe as a treatment for rheumatoid arthritis patients.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - September 28, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Easy Investing Secrets to an Early Retirement - September 25, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
How Trading Your Own Retirement Can Fleece Your Financial Future - September 22, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
AbbVie (ABBV) Stock Moves -1.13%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $89.09, moving -1.13% from the previous trading session.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - September 21, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO
by Zacks Equity Research
Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
RH, Edgewell Personal Care, Home Depot, AbbVie and QUALCOMM highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
RH, Edgewell Personal Care, Home Depot, AbbVie and QUALCOMM highlighted as Zacks Bull and Bear of the Day
3 Stocks to Buy Now for Growth & Dividends to Counter Low Bond Yields
by Benjamin Rains
Investors might want to consider buying stocks that also provide income via dividends given the current interest rate environment...